



Organised by Karnataka Ophthalmic Society



19th Annual Conference of Vitreo Retina Society of India 2010

December 2 - 4, 2010, Mysore



LUCENTIS®: the new standard of efficacy in neovascular AMD^{1,4}

- 90% or more patients treated with LUCENTIS® maintained vision (defined as losing <15 letters) at 1 and 2 years, regardless of lesion type
- 70% or more patients treated with LUCENTIS® gained ≥0 letters of vision at 1 and 2 years, regardless of lesion type
- LUCENTIS® is proven to help restore patients' independence, and patients treated with LUCENTIS® report improvements in the ability to perform everyday activities such as reading
- 90% of patients in MARINA and 83% of patients in ANCHOR remained on LUCENTIS® through 2 years
- LUCENTIS® offers an individualised treatment regimen for sustained results

References: 1. Rosenfeld PJ, Brown DM, Heier JJ, et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. 2. Data on file, Novartis Pharma AG, Basel, Switzerland. 3. LUCENTIS® summary of product characteristics. Basel, Switzerland: Novartis Pharma AG; 2006. 4. Brown DM, Kaiser PK, Michalek M, et al. for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.

Before prescribing LUCENTIS®, please consult the accompanying full national prescribing information approved in your country.





LUCENTIS® 30 mg/ml solution for injection. Presentation: Ranibizumab. Each vial contains 3.0 mg of ranibizumab in 0.3 mL solution. Indications: Treatment of neovascular (wet) age-related macular degeneration (AMD). Dosage: The recommended dose is 0.3 mg (0.35 mL). Treatment initiated with a loading phase of one injection per month for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity at a monthly basis. The interval between two doses should not be shorter than 1 month. LUCENTIS® must be administered by a qualified ophthalmologist using aseptic techniques. Broad spectrum topical antibiotics and anaesthetics should be administered prior to the injection. The patient should be instructed to self-administer anticholinergic drops four times daily for 3 days before and after each injection. Not recommended in children and adolescents. Contraindications: Hypersensitivity to ranibizumab or to any of the excipients, patients with active or suspected ocular or particular infections, patients with active intravitreal inflammation. Precautions/Warnings: Intravitreal injections have been associated with endophthalmitis, intravitreal inflammation, rhegmatogenous retinal detachment, vitreal float and traumatic traumatic cataract. Therefore proper aseptic injection techniques must be used. Patients should be monitored during the week following the injection to permit early treatment if an infection occurs. Intraocular pressure and the position of the optic nerve head must be monitored and managed appropriately. As with all therapeutic proteins, there is a potential for immunogenicity with LUCENTIS. Should not be used during pregnancy unless clearly necessary, use of effective contraception recommended for women of childbearing potential. Breast feeding not recommended. Following treatment patients may develop transient visual disturbances that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist. Interactions: No formal interaction studies have been performed. Adverse reactions: Very common adverse reactions are conjunctival haemorrhage, eye pain, vitreous floaters, retinal haemorrhage, intraocular pressure increased, vitreous detachment, intravitreal inflammation, eye irritation, cataract, foreign body sensation in eye, visual disturbance, diplopia, subconjunctival haemorrhage, ocular hyperaemia, visual acuity fluctuation, dry eye, vitritis. Common adverse reactions are ocular discomfort, conjunctival hyperaemia, posterior vitreous separation, retinal exudates, floaters etc. reactions, lacrimation increased, eye pruritus, conjunctivitis, maculopathy, detachment of the retinal pigment epithelium, headache. Uncommon adverse reactions are retinal degeneration, iris, vitreous, punctate keratitis, keratoconjunctivitis sicca, corneal edema, retinal disease, vitreous floaters, photopsias, cataract nucleus, anterior chamber flare, corneal edema, angle closure glaucoma, vitreous haemorrhage, uveitis, endophthalmitis, retinal detachment, vitreal float, eye haemorrhage, eyelid oedema, eyelid irritation, binocular, corneal oedema, hypopyon. Rare but serious adverse reactions related to intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, vitreal float and traumatic traumatic cataract. Puncta: Patch of eye vit. Note: Before prescribing, please read full prescribing information.



Before prescribing, please refer full prescribing information available from:
Novartis Health Care Pvt. Limited,
Pharmaceutical Division, Banner Road, Bangalore 560075,
Dr. Arora Smart Road, Marol, Mumbai 400 016
Tel: 022 2696 8800, Fax: 022 4347 0260, www.novartis.com



First Announcement



Conference Manager



Conferences & Incentives Management (I) Pvt. Ltd.
Tel: +91 80 40745800
E-mail: gautam@cimindia.net
Web: www.cimindia.net

Myretina2010 Secretariat

Retina Institute of Karnataka
#122, 5th Main Road
(Next to Venlakh Hospital)
Chamarajpet, Bangalore - 18
Ph: +91-80-22410106 / 536 (Hospital),
Fax: +91-80-26607811
e-mail: retinainstitute@sify.com

www.myretina2010.com

www.myretina2010.com

A cordial invitation



On behalf of the organizing committee it gives us great pleasure to invite you to 'Myretina' the 19th annual meeting of the VRS-I. We are proud to host this scientific meeting in the city of Mysore, rich in the heritage. Mysore is well connected by road and rail and offers fantastic opportunities for sightseeing and leisure. It will have a functional airport in 1-2 months.



We are gearing up to give you all an unforgettable experience. All arrangements are being made to make your visit as comfortable as possible. Please register early and tell us your travel plans so that we can organize things in advance. Dr Shobhit chawla is drawing up a very ambitious scientific delight with a generous sprinkling of international faculty! Do block the dates- Dec 2-4 , 2010, in your Dairy NOW and plan to bring your family to this fantastic meet.

Please await our next brochure for all the details.

Dr. N.S.Muralidhar
Chairman

Dr. Hemant Murthy
Organizing Secretary

About Venue

Mysore is one of India's oldest cities - an upcoming center for outsourcing and IT, which retains its old-world charm. The second largest city in Southern India's state of Karnataka (it lies 130km from Bangalore), Mysore is a city of palaces, gardens and sacred temples. It's known for its academic and research institutions, and also for its heritage buildings and palaces constructed by the Mysore Maharajas.



Among Mysore's most memorable sites are the lush Brindavan Gardens, with spectacular landscaping and fountains; Chamundeshwari Temple, with its 1,000 steps leading down to the city; and Mysore Palace, one of India's most dramatic national monuments. Its nighttime silhouette illuminated by 97,000 bulbs - is one of the city's most iconic images.

In addition to its striking monuments, Mysore is known for its handicrafts. Mysore silk and sandalwood soap are famous throughout India, as is the city's particular style of intricate wood carvings. To deepen the sense of place, attendees will be offered a series of optional trips, discoveries and special programs before and after the conference, including tours of historic Mysore sites, and visits to nearby wildlife sanctuaries.

Scientific program

Participating foreign faculty (confirmed)

- 1 Prof Jerry Shields
- 2 Dr Timothy Iye
- 3 Dr Praveen Duggel
- 4 Dr Gaurav Shah
- 5 Dr Caesare Forlini

Abstract submission

- ▶ All the Abstract should be mailed to abstractvrsi2010@gmail.com
- ▶ For online submission please visit www.myretina2010.com
- ▶ The abstracts submission starts from 1st of May 2010 and will close on 15th Aug 2010

Registration Details

Delegates	Before Sept 15, 2010	Up to October 31, 2010	After October 31, 2010
VRSI Members	Rs. 2200/-	Rs. 2450/-	Rs. 2750/-
Accompanying Person	Rs. 1900/-	Rs. 2150/-	Rs. 2450/-
Non-members	Rs. 2600/-	Rs. 2850/-	Rs. 3150/-
Fellows / Postgraduate Students	Rs. 1600/-	Rs. 1800/-	Rs. 2100/-
Trade Delegates	Rs. 2200/-	Rs. 2450/-	Rs. 2750/-
International Delegates	USD 130	USD 150	USD 180
Attendee Kit is subjected to availability for spot registration			
Please make all payments by Demand Draft favoring "VRSI 2010" payable at Bangalore			

- ▶ Cheques will not be acceptable
- ▶ Please send separate DDs for Registration and Accommodation
- ▶ PGs / Fellows must furnish certificate from HOD
- ▶ No refund on cancellation of Registration.

Organizing Committee

<p>Chairman Dr N S Muralidhar</p> <p>Vice Chairman Dr K S Sriprakash</p> <p>Organizing Secretary Dr Hemant Murthy</p> <p>Treasurer Dr Praveen R Murthy</p>	<p>VRSI Office Bearers</p> <p>President Dr Cyrus Shroff</p> <p>Secretary Dr Ajit Babu Majji</p> <p>Scientific Committee Dr Shobhit Chawla</p>	<p>Karnataka Ophthalmic Society</p> <p>President Dr V S Reddy</p> <p>President - elect Dr C N Gupta</p> <p>Secretary Dr Krishna Rao Addoor</p>
--	---	--